➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Colorcon
McKesson
Baxter
Express Scripts
Dow
Mallinckrodt

Last Updated: September 23, 2021

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE

➤ Get the DrugPatentWatch Daily Briefing

« Back to Dashboard

All Clinical Trials for Morphine Sulfate; Naltrexone Hydrochloride

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00415597 ↗ Study of Embeda (Kadian NT, ALO-01) in Subjects With Chronic Moderate to Severe Nonmalignant Pain Completed Pfizer Phase 3 2006-12-01 Open-Label, Safety Study to evaluate the long-term safety of Kadian NT (ALO-01) administered for up to 12 months.
NCT00420992 ↗ A Study of Embeda (Kadian NT, ALO-01) in Subjects With Pain Due to Osteoarthritis of the Hip or Knee Completed Pfizer Phase 3 2006-12-01 The purpose of this study is to evaluate the efficacy of Kadian NT (ALO-01) compared with placebo for treating moderate to severe chronic pain over a 12 week period.
NCT01179191 ↗ Conversion to Embeda With Rescue Trial Terminated Pfizer Phase 4 2010-08-01 The purpose of the research study is to find out if opioid dependent chronic pain patients who are judged by their physician to be eligible to change their current opioid medicine and to participate in this study can be successfully adjusted to a stable dose of EMBEDA (morphine sulfate and naltrexone hydrochloride). The study will also assess each patient's risk for prescription opioid abuse, misuse and diversion.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Morphine Sulfate; Naltrexone Hydrochloride

Condition Name

Condition Name for Morphine Sulfate; Naltrexone Hydrochloride
Intervention Trials
Pain 2
Healthy 2
Osteoarthritis 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Morphine Sulfate; Naltrexone Hydrochloride
Intervention Trials
Osteoarthritis 1
Chronic Pain 1
Chronic Disease 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Morphine Sulfate; Naltrexone Hydrochloride

Trials by Country

Trials by Country for Morphine Sulfate; Naltrexone Hydrochloride
Location Trials
United States 93
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Morphine Sulfate; Naltrexone Hydrochloride
Location Trials
Florida 4
California 4
Pennsylvania 3
Michigan 3
Missouri 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Morphine Sulfate; Naltrexone Hydrochloride

Clinical Trial Phase

Clinical Trial Phase for Morphine Sulfate; Naltrexone Hydrochloride
Clinical Trial Phase Trials
Phase 4 2
Phase 3 2
Phase 1 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Morphine Sulfate; Naltrexone Hydrochloride
Clinical Trial Phase Trials
Completed 4
Recruiting 1
Terminated 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Morphine Sulfate; Naltrexone Hydrochloride

Sponsor Name

Sponsor Name for Morphine Sulfate; Naltrexone Hydrochloride
Sponsor Trials
Pfizer 4
Ranbaxy Inc. 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Morphine Sulfate; Naltrexone Hydrochloride
Sponsor Trials
Industry 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Express Scripts
McKesson
Dow
AstraZeneca
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.